Belgium-based Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, plans to open a new 11,000- square foot U.S.-based manufacturing facility at the Minnesota Bio Business Center in downtown Rochester, Minnesota.
The facility will also serve as a base for the Company’s research and clinical collaboration with Mayo Clinic, also based in Rochester. In addition, the new center will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure, and its recently acquired CAR T-cell therapies’ portfolio.
C-Cure is an autologous cellular therapy for the treatment of congestive heart failure that is based on the Company’s proprietary Cardiopoiesis platform, initially developed using fundamental research and proprietary technology from the Mayo Clinic.
Christian Homsy, CEO of Cardio3 BioSciences said, “ We are very thankful to Rochester, RAEDI and DEED for the efforts that they made in facilitating the public assistance and location for our facility. Our plans for this facility will first be to manage the manufacturing-related activities associated with the U.S. portion of CHART-2, our second global Phase III clinical trial for C-Cure.”
Cardio3 BioSciences will receive non-dilutive funding from the Minnesota Department of Employment and Economic Development and the Minnesota Job Creation Fund once it completes its investment and hiring goals.
RAEDI President Gary Smith said, “Securing Cardio3 BioSciences’ newest United States location in Rochester is the result of an expansive effort led by Rochester Area Economic Development, the City of Rochester, Mayo Clinic, and the Minnesota Department of Employment and Economic Development, and we appreciate all who championed the endeavour. Cardio3 BioSciences will anchor our area’s emerging Regenerative Medicine Cluster with its focus on developing leading cellular therapies, and we encourage members of the community to welcome the Company.”